Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Shares Issued (2016 - 2026)

Akebia Therapeutics has reported Shares Issued over the past 10 years, most recently at -$430000.0 for Q3 2025.

  • Quarterly Shares Issued fell 102.11% to -$430000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $230000.0 through Dec 2025, down 40.26% year-over-year, with the annual reading at $230000.0 for FY2025, 40.26% down from the prior year.
  • Shares Issued was -$430000.0 for Q3 2025 at Akebia Therapeutics, down from $582000.0 in the prior quarter.
  • Over five years, Shares Issued peaked at $72.4 million in Q4 2021 and troughed at -$20.0 million in Q4 2024.
  • The 5-year median for Shares Issued is $800000.0 (2022), against an average of $9.2 million.
  • The largest YoY upside for Shares Issued was 55017.65% in 2024 against a maximum downside of 54811.76% in 2024.
  • A 5-year view of Shares Issued shows it stood at $72.4 million in 2021, then tumbled by 90.26% to $7.1 million in 2022, then decreased by 4.91% to $6.7 million in 2023, then crashed by 398.4% to -$20.0 million in 2024, then surged by 97.85% to -$430000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Shares Issued are -$430000.0 (Q3 2025), $582000.0 (Q2 2025), and $78000.0 (Q1 2025).